Alan H. Auerbach has served as our Chairman of the Board and as our Chief Executive Officer and President since our inception. Prior to founding Puma, Mr. Auerbach served as Founder, Chief Executive Officer, President and a Member of the Board of Directors of Cougar Biotechnology, Inc., from the company's inception in 2003 until its acquisition by Johnson & Johnson in July 2009.

From July 2009 until January 2010, Mr. Auerbach served as Co-Chairman of the Integration Steering Committee at Cougar (as part of Johnson & Johnson) that provided leadership and oversight for the development and global commercialization of Cougar's lead product candidate, abiraterone acetate. Abiraterone was approved for the treatment of metastatic prostate cancer in the U.S. in April 2011 and in the European Union in September 2011.

Prior to founding Cougar, from June 1998 to April 2003 Mr. Auerbach was Vice President, Senior Research Analyst at Wells Fargo Securities, where he was responsible for research coverage of small- and middle- capitalization biotechnology companies, with a focus on companies in the field of oncology. He had primary responsibility for technical, scientific and clinical due diligence, as well as selection of biotechnology companies followed by the company. During 2002, Mr. Auerbach ranked second in the NASDAQ/Starmine survey of analyst performance for stock picking in biotechnology. From August 1997 to May 1998, Mr. Auerbach was a Vice President, Research Analyst at the Seidler Companies, Inc., where he was responsible for research coverage of small-capitalization biotechnology companies. Prior to his work as a biotechnology analyst, Mr. Auerbach worked for Diagnostic Products Corporation, where he designed and implemented Clinical Trials in the field of oncology.

Mr. Auerbach received a B.S. in Biomedical Engineering from Boston University and an M.S. in Biomedical Engineering from the University of Southern California.

Mr. Nougues joined Puma Biotechnology as Chief Financial Officer in November 2018.

Mr. Nougues worked for Getinge AB, a global medical device company based in Sweden, from January 2008 until October 2018. At Getinge, he held several leadership positions with oversight for the business that generated regional revenues of approximately $1 billion annually. During his tenure at Getinge, he served as regional chief financial officer for North America, regional chief financial officer for the Americas, and regional vice president and chief financial officer for MAQUET North America, which was acquired by Getinge in 2000. Prior oining Getinge, Mr. Nougues worked in finance roles in Boston Scientific’s cardiac surgery division, which was acquired by Getinge in 2008, and at The Clorox Company from 1998 until 2007.

Mr. Nougues holds an M.S. in business administration from the Universidad del Norte Santo Tomas de Aquino, Tucuman, Argentina and an M.B.A. from the University of San Francisco McLaren School of Business.

Mr. Hunt joined Puma Biotechnology as Senior Vice President of Regulatory Affairs, Medical Writing and Project Management in January 2018. Mr. Hunt has over 25 years of regulatory affairs experience and was a regulatory affairs consultant to Puma from February 2017 to January 2018.

Mr. Hunt previously served as Vice President Regulatory Affairs and Quality Assurance at ArmaGen Inc., from March 2015 to December 2017, where he supported the development of multiple products designed to cross the Blood Brain Barrier. He served as Vice President Global Regulatory Affairs (Bioscience) at Baxter International from 2008 to 2015. During his tenure at Baxter, he was responsible for global regulatory affairs for several franchises including oncology. Notably, he supported the successful U.S. advisory Committee that supported the approval of HyQuvia. From March 2000 to July 2008, Mr. Hunt held various roles at Amgen, including as Executive Director, Therapeutic Area Head (Oncology) and Executive Director, Therapeutic Area Head (Bone/Oncology), Global Regulatory Affairs and Safety. During his tenure at Amgen, he supported the development and approval of Neulasta, Aranesp, Enbrel and NPlate. Prior to joining Amgen, Mr. Hunt worked for Quintiles, providing regulatory support to multiple development programs.

Mr. Hunt received a B.Sc (Hons). from the University of Portsmouth (UK). He is a Fellow of the Regulatory Affairs Professionals Society.

Ms. Blaber joined Puma Biotechnology, as Vice President of Marketing in June 2021. She brings more than 25 years of strategic marketing and sales leadership experience within the biopharmaceutical industry. Throughout her career, Ms. Blaber has built a reputation for leading high-performing teams, launching blockbuster products, and driving market share in highly competitive therapeutic areas. Her work has earned numerous awards, including the PM360 Brand Champion Award in the Women’s Health category in September, 2022.

Prior to joining Puma, Ms. Blaber held both District and Regional Sales Director roles at Amgen in Bone Health, Cardiovascular, Neurosciences and Plaque Psoriasis. She also served as Marketing Director for Amgen’s NEUPOGEN®/Neulasta® and Vectibix® franchises, where she led the development of key promotional strategies and marketing campaigns, which resulted in significant business growth and industry recognition. She began her pharmaceutical career in sales at Pfizer and has also held leadership positions at Wyeth.

Ms. Blaber holds a B.A. in Communications with a concentration in Business and Marketing from California Polytechnic State University. She has also completed executive leadership coursework at UCLA Anderson.

Mr. Esplin joined Puma Biotechnology as Vice President Finance in October 2020. He has over 25 years of experience in accounting and finance and is licensed as a Certified Public Accountant.

Mr. Esplin worked for MX Technologies, a privately held fintech company, from 2015 to 2020. At MX, he built accounting processes, systems and infrastructure to support revenue growth rates of 25% to 100% annually. From 2007 to 2015 he worked at Amedica Corporation (now SINTX Technologies), a public orthopedic implant company where he supported financial diligence and capital raise activities which generated more than $100 million in private equity financing, in various roles, including as Controller, Vice President Finance and Principal Accounting Officer. Additionally, Mr. Esplin managed all financial reporting, accounting and treasury functions, taxes, budgeting, and led the finance team in a successful IPO process to become publicly listed on NASDAQ in 2014.

Prior to joining Amedica, Mr. Esplin worked at NPS Pharmaceuticals from 2004 to 2007 where he served as Corporate Controller, Director of FP&A and Senior Manager, Financial Compliance. He began his career in public accounting working for Arthur Andersen and PwC from 1994 to 2004.

Mr. Esplin holds an M.S. in business information systems and a B.S in Accounting from Utah State University. He is an active member of the American Institute of Certified Public Accountants and the Utah Association of Certified Public Accountants.

Ms. Sacman joined Puma Biotechnology in November 2011 as Vice President, Quality Assurance. She currently serves as Senior Vice President, Quality Assurance, leading Puma’s quality and compliance functions.

Prior to joining Puma, she was part of the Cougar Biotechnology team that developed and obtained approval of Zytiga®. She has held senior management and scientist roles at Johnson & Johnson, Elan Pharmaceuticals, ALZA Corporation, and Scios, where she supported development and commercialization of various drugs, including Tysabri®, Prialt®, Duragesic®, Concerta®, and Natrecor®. She has held management consulting roles at OXiGENE, Genentech, and other companies globally to establish quality organizations and build compliant systems and processes.

Ms. Sacman received a B.S. in Systems Physiology from San Jose State University and an M.S. in Applied Biology from the University of Southern California.

Mr. Storms joined Puma Biotechnology in December 2024, bringing with him more than 20 years of commercial leadership experience in the biopharmaceutical industry.

Prior to Puma, Mr. Storms spent 11 years at Amgen Biotechnology, where he held roles of increasing responsibility, most recently serving as Eastern U.S. Director of Sales. In this capacity, he led commercial efforts that generated over $3 billion in annual revenue and successfully led the launch of 7 new novel therapies. His earlier experience includes 12 years at Boehringer Ingelheim, where he built and led high-performing sales teams while deepening his expertise in commercial operations.

Mr. Storms’ extensive industry background, proven ability to drive top-line growth, and passion for team development position him exceptionally well to lead our sales organization into its next chapter.

Mr. Storms' educational background includes both B.S and M.S. degrees from the University of Southern Indiana, as well as a B.A. from Indiana University Bloomington.

Mr. Wiehe joined Puma Biotechnology in March 2017 as Senior Director, Global Supply Chain and Logistics and currently serves as Senior Vice President, Supply Chain and Manufacturing.

Mr. Wiehe is responsible for Manufacturing and Global Supply Chain and Logistics for all clinical and commercial operations at Puma. He has over 25 years of industry experience spanning manufacturing, supply chain, project management, and process development. Prior to joining Puma, he held positions of increasing responsibility with Dynavax Technologies, Shire, Novartis, and Amgen.

Mr. Wiehe earned a B.S. in Environmental Science at St. Michael’s College and an M.B.A. from the Haas School of Business at the University of California, Berkeley.

Ms. Wilson joined Puma Biotechnology as Vice President, Clinical Operations in December 2013. Ms. Wilson has over 30 years of clinical operations experience in pharmaceutical and biotechnology companies, as well as Clinical Research Organizations. In her current role, she also has responsibility for the Clinical Finance, Records Management and Clinical Quality Liaison groups.

Prior to joining Puma, Ms. Wilson served as Executive Director, Clinical Operations at Anacor Pharmaceuticals providing oversight to multiple studies within the tavaborole program.

From 1993 to 2011, Ms. Wilson worked for Clinimetrics Research Associates, a global, mid-size CRO where she held multiple positions beginning with Clinical Research Associate and rising to Chief Operations Officer in 2007. During her tenure with Clinimetrics, she supported Roche Pharmaceuticals on the CellCept program, serving as Project Manager on over 22 studies and later provided significant oversight to Amylin’s Byetta program. Following a multi-CRO acquisition by Omnicare, she was named Senior Vice President, Clinical Development and was responsible for oversight of the Phase III Business Unit as well as re-organizing Global Safety across the two organizations building units in the US, Germany, India, China and Australia under the re-branded organization known as Theorem.

Ms. Wilson received a B.A. in Economics from the University of Oregon.